Irinquiries@prestigebrands.com
Prestige Consumer Healthcare Inc.
660 White Plains Road – Ste 250
Tarrytown, NY 10591
Telephone: 914-524-6819
|
MESSAGE FROM OUR CHAIR AND CEO
Ronald M. Lombardi President, Chief Executive Officer and Chair of the Board
|
| |
|
|
|
|
|
|
Ronald M. Lombardi President, Chief Executive Officer and Chair of the Board |
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
1
|
|
|
|
| | |
|
| | |
|
|
|
WHEN:
|
| | |
WHERE:
|
| | |
WHO:
|
|
|
Tuesday, August 6, 2024
10:00 a.m. (Eastern Daylight Time) |
| | |
At the Company’s offices
660 White Plains Road Tarrytown, New York 10591 |
| | |
Only stockholders of record at the close
of business on June 10, 2024 will be entitled to vote at the Annual Meeting. |
|
|
1
|
| |
Elect the seven directors nominated by the Board of Directors and named in the accompanying Proxy Statement to serve until the 2025 Annual Meeting of Stockholders or until their earlier death, removal or resignation
|
|
|
2
|
| |
Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Prestige Consumer Healthcare Inc. for the fiscal year ending March 31, 2025
|
|
|
3
|
| |
Conduct an advisory vote to approve the compensation of our named executive officers
|
|
|
4
|
| |
Approve a proposal for the Amendment to our Amended and Restated Certificate of Incorporation
|
|
|
5
|
| |
Conduct other business as may properly be brought before the 2024 Annual Meeting of Stockholders or any adjournment or postponement thereof, including proposals to adjourn or postpone the meeting
|
|
|
|
| |
By Order of the Board of Directors,
William C. P’Pool
Senior Vice President, General Counsel & Corporate Secretary July 5, 2024
|
|
|
WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL MEETING IN PERSON, PLEASE PROMPTLY COMPLETE, SIGN, DATE AND MAIL THE ENCLOSED PROXY CARD, OR VOTE BY THE INTERNET ACCORDING TO THE INSTRUCTIONS ON YOUR PROXY CARD. A SELF-ADDRESSED POSTAGE PAID RETURN ENVELOPE IS ENCLOSED FOR YOUR CONVENIENCE. NO POSTAGE IS REQUIRED IF MAILED IN THE UNITED STATES. IF YOU DO ATTEND THE ANNUAL MEETING, YOU MAY WITHDRAW YOUR PROXY SHOULD YOU WISH TO VOTE IN PERSON. YOU MAY REVOKE YOUR PROXY BY FOLLOWING THE INSTRUCTIONS ON PAGE 76 OF THE PROXY STATEMENT.
|
|
|
If you own shares in a brokerage account, your bank or brokerage firm forwarded these proxy materials, as well as a voting instruction card, to you. Please follow the instructions on the voting instruction card to vote your shares. Your broker cannot vote your shares for proposals regarding the election of our directors, approval of the compensation of our named executive officers or the amendment to our certificate of incorporation unless you provide voting instructions to your broker. Therefore, it is very important that you exercise your right as a stockholder and vote on all proposals.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
2
|
|
| | | |
PAGE
|
| |||
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 9 | | | |
| | | |
|
| | ||
| | | | | 29 | | | |
| | | | | 31 | | | |
| | | | | 32 | | | |
| | | | | 34 | | | |
| | | | | 36 | | | |
| | | | | 67 | | | |
| | | | | 68 | | | |
| | | | | 69 | | | |
| | | | | 71 | | | |
| | | | | 72 | | | |
| | | | | 73 | | | |
| | | | | 75 | | | |
| | | | | 78 | | |
|
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDERS MEETING TO BE HELD ON AUGUST 6, 2024:
|
|
|
This Proxy Statement, the Proxy Card and the 2024 Annual Report to Stockholders are available at the “investors” tab of www.prestigeconsumerhealthcare.com, our internet website.
|
|
|
You can submit a request for a copy of the Proxy Statement, Annual Report and Form of Proxy for any future stockholder meetings (including the meeting of stockholders to be held on August 6, 2024) to 1-800-831-7105, (Attention: Investor Relations), proxy@prestigebrands.com or the “contact us” tab at www.prestigeconsumerhealthcare.com.
|
|
|
You can also contact us at the phone number, e-mail address and website set forth above to request directions to the location of the Annual Meeting of Stockholders so that you may attend the meeting and vote in person.
|
|
|
|
| | |
|
| | |
|
|
|
WHEN:
|
| | |
WHERE:
|
| | |
WHO:
|
|
|
Tuesday, August 6, 2024
10:00 a.m. (Eastern Daylight Time) |
| | |
At the Company’s offices
660 White Plains Road Tarrytown, New York 10591 |
| | |
Only stockholders of record at the close
of business on June 10, 2024 will be entitled to vote at the Annual Meeting. |
|
|
PROPOSAL
|
| | BOARD’S RECOMMENDATION |
| |
SEE
PAGE |
| |||||||||||||||
|
1
|
| |
To elect the seven directors nominated by the Board of Directors and named in this Proxy Statement to serve until the 2025 Annual Meeting of Stockholders or until their earlier death, removal or resignation
|
| |
|
| |
FOR each director nominee
|
| |
19
|
| |||||||||
| | | |
☐
Ronald M.
Lombardi
|
| |
☐
John E.
Byom
|
| |
☐
Celeste A.
Clark
|
| |
☐
James C. D’Arecca
|
| | | | | | | | | |
| | | |
☐
Sheila A.
Hopkins
|
| |
☐
John F.
Kelly
|
| |
☐
Dawn M.
Zier
|
| | | | | | | | | | | | |
|
2
|
| |
To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Prestige Consumer Healthcare Inc. for the fiscal year ending March 31, 2025
|
| |
|
| |
FOR
|
| |
29
|
| |||||||||
|
3
|
| |
To vote on a non-binding resolution to approve the compensation of our named executive officers as disclosed in our Proxy Statement
|
| |
|
| |
FOR
|
| |
31
|
| |||||||||
|
4
|
| |
To vote for the approval of the Amendments to our Amended and Restated Certificate of Incorporation
|
| |
|
| |
FOR
|
| |
32
|
|
|
|
| |
BY INTERNET
Visit, 24/7, access www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. |
| |
|
|
|
|
| |
BY MAIL
Complete, date and sign your proxy card and send by mail in the enclosed postage-paid envelope |
| |||
|
|
| |
IN PERSON
Attend the annual meeting and cast your ballot |
|
|
This Proxy Statement and the proxy card are first being mailed or given to stockholders on or about July 5, 2024.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
4
|
|
|
Top Line Trends
|
| |
■
Revenue of $1,125 Million
■
Consumption was very strong for the year, exceeding our long-term 2 to 3% target
■
Continued strong growth in International OTC segment
|
|
|
EPS
|
| |
■
Adjusted EPS of $4.21
■
Strong financial profile leading to sustained profitability
|
|
|
Free Cash Flow & Allocation
|
| |
■
Adjusted Free Cash Flow of about $240 million
■
Reduced debt to lowest level in recent Company history, which enables future capital allocation optionality
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
5
|
|
|
Prestige Consumer Healthcare’s Board of Directors, management and employees all recognize the responsibility that comes with selling trusted consumer healthcare brands, and the importance of integrating corporate sustainability into our operations and culture for the benefit of future generations. We are committed to building environmental sustainability, social responsibility, and effective corporate governance into all aspects of our business. We view this as sound business strategy that drives resiliency and long-term value creation for the benefit of all stakeholders, including our consumers, customers, employees, investors, suppliers, regulators and the communities in which we live and operate.
|
|
|
We developed a roadmap for implementation of our ESG program and retained a third-party sustainability consulting firm to assist us with our planning and materiality assessment. We published our inaugural corporate sustainability report in 2023, which is available on our website, esg.prestigeconsumerhealthcare.com. We will publish our 2024 corporate sustainability report later in 2024. Our approach to ESG is based on credible frameworks and standards that create a foundation for identifying material ESG topics, understanding our ESG risks and opportunities, and informing our ESG strategy. We also understand the importance of preparing for market transformations by staying proactive in our strategy and preparing for increased transparency with our stakeholders, along with shifts in regulations, such as the SEC climate risk disclosures.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
6
|
|
|
LEADERSHIP
|
| |
TRUST
|
| |
CHANGE
|
| |
EXECUTION
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
7
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
8
|
|
|
Good governance practices are imperative for aligning the interests of individuals, the organization and society. The Board of Directors provides oversite of the Company’s strategy, risks and governance, including ESG.
|
|
|
Board Accountability. All directors stand for election each year subject to a resignation policy if they do not receive a majority.
Director Independence. 6 of 7 director nominees are independent and all members of each committee are independent.
Board Leadership. Annual assessment of Board leadership structure and strong Lead Independent Director role appointed each year.
Director Engagement. Robust attendance for Board and committee meetings in 2024; all directors attended more than 75% of the meetings of the Board and the Committees on which they served.
Board Diversity. Diverse and experienced Board comprised of individuals with different backgrounds, relevant experiences, ages, gender and ethnic diversity.
Regular Executive Sessions. All regularly scheduled Board and committee meetings provide an opportunity for the directors to meet without management present.
Board and Committee Self-Evaluations. The Board and each of its committees conducts a self-evaluation of its performance on an annual basis, with individual assignment and follow-up for any items identified as a part of continuous improvement efforts.
No Overboarding. Nonemployee directors are limited to no more than four public company boards in addition to the Company, and the CEO is limited to one board in addition to the Company.
|
| | |
Director Access and Resources. Board members have significant interaction with and direct access to senior business leaders and outside experts.
Stockholder Rights. Stockholders may act by written consent.
Regular Review of Key Governance Documents. Annual review of Committee Charters, Corporate Governance Guidelines and Code of Conduct and Ethics.
Compensation Best Practices. Including annual Say on Pay vote, implementation of “double trigger” change-in-control vesting provisions, provisions for awards that are assumed in connection with a change-in-control, no excise tax reimbursements for change-in-control payments, strict policy of no hedging and limited pledging of common stock by directors and executive officers, clawback policy and stock ownership guidelines.
Robust Code of Conduct and Ethics. Promotes honest and ethical conduct throughout the Company and all employees receive regular online training.
Robust Risk Management/ESG Oversight. The Board and designated committees exercise oversight of management’s risk assessment and management processes and findings and oversee the Company’s sustainability/ESG strategy and initiatives.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
9
|
|
| | | | | | | | |
|
■
Code of Conduct and Ethics
|
| | | | |
■
Code of Ethics for Senior Financial Employees
|
|
| | | | | | | | |
|
■
Charters of our Audit and Finance, Compensation and Talent Management and Nominating and Corporate Governance Committees
|
| | | | |
■
Corporate Governance Guidelines
■
Insider Trading Policy
|
|
|
ON OUR CORPORATE WEBSITE
|
| |
BY WRITING TO
|
|
| www.prestigeconsumerhealthcare.com | | | Prestige Consumer Healthcare Inc. Attention: Corporate Secretary 660 White Plains Road Tarrytown, New York 10591 |
|
|
We want to hear from you
|
| |
Stockholders and other interested parties may send communications to the Board of Directors
or any committee thereof or any individual director by writing to the Board of Directors, such committee or such individual director at Prestige Consumer Healthcare Inc., 660 White Plains Road, Tarrytown, New York 10591, Attention: Corporate Secretary. The Corporate Secretary will distribute all stockholder and other interested party communications to the intended recipients and/or to the entire Board of Directors, as appropriate. |
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
10
|
|
| | | | | |
|
The Board of Directors held five meetings during fiscal 2024. Each director is expected to attend each meeting of the Board of Directors and those committees on which he or she serves. The Board of Directors expects that its members will attend the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) either in person, by videoconference or by telephone. All our directors attended the 2023 Annual Meeting of Stockholders.
|
| |
≥75% ATTENDANCE
Each of our directors attended 75% or more of the total number of meetings of the Board of Directors and those committees on which he or she served during the last fiscal year.
|
|
| | | | | |
|
100%
|
| |
As required by the NYSE, all members of the Audit and Finance, Compensation and Talent Management and Nominating and Corporate Governance Committees are independent directors.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
11
|
|
| AUDIT AND FINANCE |
|
|
■
James C. D’Arecca (Chair)
|
|
|
■
John E. Byom
|
|
|
■
Sheila A. Hopkins
|
|
|
■
Dawn M. Zier
|
|
| COMPENSATION & TALENT MANAGEMENT |
|
|
■
Dawn M. Zier (Chair)
|
|
|
■
John E. Byom
|
|
|
■
Celeste A. Clark
|
|
|
■
John F. Kelly
|
|
|
■
Natale S. Ricciardi*
|
|
| NOMINATING & CORPORATE GOVERNANCE |
|
|
■
Celeste A. Clark (Chair)
|
|
|
■
James C. D’Arecca
|
|
|
■
Sheila A. Hopkins
|
|
|
■
John F. Kelly
|
|
|
■
Natale S. Ricciardi*
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
12
|
|
|
AUDIT AND FINANCE COMMITTEE
|
| |
MEETINGS IN 2024: 4
|
| ||||||
|
JAMES C. D’ARECCA
(CHAIR) |
| |
JOHN E. BYOM
|
| |
SHEILA A. HOPKINS
|
| |
DAWN M. ZIER
|
|
|
The Audit and Finance Committee is responsible for, among other things:
■
the appointment, compensation, retention and oversight of the work of the independent registered public accounting firm engaged for the purpose of preparing and issuing an audit opinion on our annual financial statements;
■
reviewing the independence of the independent registered public accounting firm and taking, or recommending that the Board of Directors take, appropriate action to oversee their independence;
■
approving, in advance, all audit and non-audit services to be performed by the independent registered public accounting firm;
■
overseeing our accounting and financial reporting processes and the audits of our financial statements;
■
establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal control or auditing matters and the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters;
■
engaging independent counsel and other advisers as the Audit and Finance Committee deems necessary;
■
determining compensation of advisors hired by the Audit and Finance Committee and ordinary administrative expenses;
|
| |
■
providing advice and counsel to management on financial strategy, capital structure and capital allocation;
■
reviewing and assessing the adequacy of the Audit and Finance Committee’s formal written charter on an annual basis;
■
reviewing policies for risk assessment and risk management, including meeting with management at least annually to review the Company’s strategic, enterprise risk exposures, concentrations and mitigation measures undertaken by management to monitor and control those exposures;
■
reviewing policies with respect to the Company’s information technology (IT) systems, privacy, information governance and cybersecurity management, including meeting with management at least annually to review the Company’s IT security program, compliance and controls with the Chief Information Security Officer, and the steps management has taken to monitor and mitigate such cyber and privacy exposures;
■
oversight of the impact of new and proposed ESG disclosure laws and regulatory requirements, filings, controls and procedures; and
■
handling such other matters as are specifically delegated to the Audit and Finance Committee by the Board of Directors from time to time.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
13
|
|
|
COMPENSATION & TALENT MANAGEMENT COMMITTEE
|
| |
MEETINGS IN 2024: 5
|
| |||||||||
|
DAWN M. ZIER (CHAIR)
|
| |
JOHN E. BYOM
|
| |
CELESTE A. CLARK
|
| |
JOHN F.KELLY
|
| |
NATALE S. RICCIARDI
|
|
|
The Compensation and Talent Management Committee is responsible for, among other things:
■
determining the compensation and benefits of all our executive officers;
■
recommending to the Board of Directors the compensation for non-employee directors;
■
reviewing our compensation and benefit plans to ensure that they meet corporate objectives, as well as evaluating the risk associated with the compensation and benefit plans;
■
administering our stock plans and other incentive compensation plans;
|
| |
■
approving the annual corporate goals and objectives of the CEO and executive officers and evaluating their performance against those goals and objectives;
■
reviewing succession planning for senior management and along with the Nominating and Corporate Governance Committee, for the CEO;
■
oversight of the development, implementation, and effectiveness of the Company’s policies and strategies related to its human capital management, including matters related to diversity, equality, and inclusion, and talent management; and
■
handling such other matters as are specifically delegated to the Compensation and Talent Management Committee by the Board of Directors from time to time.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
14
|
|
|
NOMINATING & CORPORATE
GOVERNANCE COMMITTEE |
| |
MEETINGS IN 2024: 5
|
| |||||||||
|
CELESTE A. CLARK (CHAIR)
|
| |
JAMES C. D’ARECCA
|
| |
SHEILA A. HOPKINS
|
| |
JOHN F. KELLY
|
| |
NATALE S. RICCIARDI
|
|
|
The Nominating and Corporate Governance Committee is responsible for, among other things:
■
selecting, and recommending to the Board of Directors for selection, nominees for election to the Board of Directors;
■
making recommendations to the Board of Directors regarding the size and composition of the Board of Directors and its committees;
■
considering and making recommendations to the Board of Directors on questions of independence and possible conflicts of interest of members of our Board and executive officers in accordance with the Corporate Governance Guidelines;
■
monitoring our performance under our principles of corporate governance;
|
| |
■
monitoring risks related to its areas of corporate responsibility and governance, including, along with the Audit Committee, the Company’s Code of Conduct and Ethics;
■
reviewing succession planning and refreshment for the Board;
■
succession planning for the CEO together with the Compensation and Talent Management Committee;
■
oversight of the Company’s responsibilities as a corporate citizen pertaining to corporate social responsibility and global sustainability including environmental, social and corporate governance policies and practices, responsible sourcing, community impact and corporate reputation; and
■
handling such other matters as are specifically delegated to the Nominating and Corporate Governance Committee by the Board of Directors from time to time.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
15
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
16
|
|
|
AUDIT & FINANCE
COMMITTEE OVERSIGHT RESPONSIBILITIES |
| |
COMPENSATION & TALENT
MANAGEMENT COMMITTEE OVERSIGHT RESPONSIBILITIES |
| |
NOMINATING & CORPORATE
GOVERNANCE COMMITTEE OVERSIGHT RESPONSIBILITIES |
|
|
■
Overall risk exposures and enterprise risk management process;
■
Risks related to financial statements and the financial reporting process;
■
Accounting, legal, ethics and compliance matters;
■
Internal audit and the risk control organization including any significant changes to corporate risk control policies;
■
Risks related to information technology systems, privacy and cyber security management (including annual review of the structure and sufficiency of cyber security mitigation efforts, including cyber risk insurance);
■
Financial risk related to ESG matters; and
■
Risks related to liquidity and capital allocation.
|
| |
■
Risks associated with the Company’s compensation philosophy and programs;
■
Engages an independent consultant to support in reviewing compensation programs and policies to encourage appropriate risk taking;
■
Talent acquisition and retention risks; and
■
Human capital management and issues related to diversity, inclusion and belonging.
|
| |
■
Risks related to corporate governance, including the Corporate Governance Guidelines;
■
Along with the Audit and Finance Committee, the Company’s Code of Conduct and Ethics;
■
Corporate responsibility, sustainability and ESG related risks and opportunities; and
■
Succession planning for the Board and CEO.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
17
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
18
|
|
|
Annual Election of Directors. All directors stand for election on an annual basis.
Majority Voting Uncontested Director Elections. Any director nominee must resign if they do not receive an affirmative vote of a majority of votes cast in an uncontested election. The Board will then determine whether to accept the resignation and disclose any decision not to accept the resignation.
Director Independence. 6 out of 7 director nominees are independent (all directors are independent other than the CEO; fully independent Audit and Finance Committee, Compensation and Talent Management Committee and Nominating and Corporate Governance Committee).
|
| | |
Independent Board Leadership. Our Board of Directors maintains a Lead Independent Director who meets regularly with our independent members in executive session.
Board Refreshment. 4 of our 6 independent Board nominees have joined in the last 5 years and have expanded the Board’s scope of experience.
Financial Literacy for Audit Committee. Three current Audit and Finance Committee members are “audit committee financial experts” under SEC rules.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
19
|
|
|
|
| |
Leadership Experience. We believe that directors with experience in significant leadership positions over an extended period, especially chief executive officer positions, chief financial officers and other senior executives, provide the Company with valuable insights and strategic thinking. These individuals generally possess extraordinary leadership qualities and the ability to identify and develop those qualities in others. They demonstrate a practical understanding of organizations, processes, strategy, risk management and the methods to drive change and growth.
|
|
|
|
| |
Finance Experience. We believe that an understanding of finance and the financial reporting process is important for our directors. We measure our operating and strategic performance by reference to financial targets. In addition, accurate financial reporting and robust auditing are critical to our success and developing stockholders’ confidence in our reporting processes under the Sarbanes-Oxley Act of 2002. We expect all of our directors to be financially literate.
|
|
|
|
| |
Consumer Products Experience. As a marketer and distributor of brand name personal healthcare products throughout the U.S. and Canada, Australia, and in certain other international markets, we seek directors with experience as executives managing consumer products businesses.
|
|
|
|
| |
Marketing Experience. The Company seeks to grow organically by identifying and developing opportunities for expanding distribution of its existing product offerings through traditional and digital marketing, while also developing and launching new products to sell into the market. We seek directors with a strong marketing background.
|
|
|
|
| |
Environmental, Social & Governance. As a global corporate citizen, we believe that sustainable operations are both financially and operationally beneficial to our business, and critical to the health of our employees and the communities in which we operate. We seek directors with experience in building strong environmental, labor, health & safety and ethical practices.
|
|
|
|
| |
Supply Chain Experience. The Company relies on third party manufacturers and its own manufacturing facilities in Lynchburg, Virginia and Victoria, Australia to fulfill its manufacturing needs. As a result, we seek to have directors with experience in supply chain management, quality and compliance with the various regulations that govern the manufacture, packaging, labeling, distribution, and importation of our products.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
20
|
|
| | | | | |
|
In evaluating potential candidates for Board membership, the Nominating and Corporate Governance Committee considers diversity of age, gender, race, socio-economic and cultural background and professional experience. We believe our Board’s current composition on which three of six independent directors are female (50% of Board), and two of whom are Ethnic Minorities (33% of Board), reflects our efforts and commitment to diversity, even though the Board does not have formal diversity requirements.
|
| |
% OF INDEPENDENT BOARD
NOMINEES |
|
|
|
| |
Recognized as a gender-balanced Board of Directors by the 50/50 Women on Boards Gender Diversity Index™ — just 9% of Russell 3000 boards are 50/50 or better.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
21
|
|
| | | |
NAME AGE
DIRECTOR SINCE |
| |
PRIMARY (OR FORMER)
OCCUPATION |
| |
INDEPENDENCE
|
| |
COMMITTEE
ASSIGNMENTS |
|
|
|
| |
Ronald M. Lombardi
60 June 2015 |
| |
Chair of the Board, President and Chief Executive Officer, Prestige Consumer Healthcare Inc.
|
| | | | | | |
|
|
| |
John E. Byom
70 January 2006 |
| |
(Former) Chief Executive Officer of Classic Provisions Inc. and Chief Financial Officer of International Multifoods Corporation.
|
| |
|
| |
Audit & Finance, Compensation & Talent Management
|
|
|
|
| |
Celeste A. Clark
71 February 2021 |
| |
(Former) Senior Vice President, Global Policy and External Affairs and Chief Sustainability Officer of Kellogg Company.
|
| |
|
| |
Compensation & Talent Management, Nominating & Corporate Governance (Chair)
|
|
|
|
| |
James C. D’Arecca
53 August 2023 |
| |
Executive Vice President, Chief Financial Officer of Haemonetics Corporation
|
| |
|
| |
Audit & Finance (Chair), Nominating & Corporate Governance
|
|
|
|
| |
Sheila A. Hopkins
68 August 2015 |
| |
(Former) Interim Chief Executive Officer of Cutera, Inc; (Former) President, Global Vision Care and Executive Vice President of Bausch + Lomb.
|
| |
|
| |
Audit & Finance, Nominating & Corporate Governance
|
|
|
|
| |
John F. Kelly
63 May 2024 |
| |
(Former) Vice President, Quality Operations and Environment, Health & Safety at Pfizer Inc.
|
| |
|
| |
Compensation & Talent Management, Nominating & Corporate Governance
|
|
|
|
| |
Dawn M. Zier
59 May 2020 |
| |
Chair of The Hain Celestial Group, Inc; (Former) President and CEO of Nutrisystem.
|
| |
|
| |
Audit & Finance, Compensation & Talent Management (Chair)
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
22
|
|
| | | | | |
BYOM
|
| |
CLARK
|
| |
D'ARECCA
|
| |
HOPKINS
|
| |
KELLY
|
| |
LOMBARDI
|
| |
ZIER
|
| |
TOTAL EXPERIENCE
|
| ||||
|
SOME
KNOWLEDGE |
| | |
DEEP
KNOWLEDGE |
| ||||||||||||||||||||||||||
|
| |
Leadership
Experience |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | | | | |
|
|
|
| |
Finance
Experience |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | |
|
|
|
| |
Consumer
Products Experience |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | |
|
|
|
| |
Marketing
Experience |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | |
|
|
|
| |
Environmental,
Social & Governance |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | |
|
|
|
| |
Supply Chain
Experience |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | |
|
|
|
|
| |
Deep Knowledge
or Experience |
| |
|
| |
Some Knowledge
or Experience |
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
23
|
|
|
John E. Byom Director
|
| |||||||||||||||
|
|
| |
CAREER HIGHLIGHTS:
John E. Byom has served as a director since January 2006. Mr. Byom was Chief Executive Officer of Classic Provisions Inc., a specialty foods distribution company, from October 2007 until the business was sold and he retired in June 2019. Mr. Byom was previously the Chief Financial Officer of International Multifoods Corporation. He left International Multifoods Corporation in March 2005 after 26 years, including four years as Vice President Finance and Chief Financial Officer from March 2000 to June 2004. After the sale of International Multifoods Corporation to The J.M. Smucker Company in June 2004, Mr. Byom was President of Multifoods Foodservice and Bakery Products. Prior to his time as Chief Financial Officer and as President of Multifoods Foodservice and Bakery Products, Mr. Byom was President of U.S. Manufacturing from July 1999 to March 2000, and Vice President Finance and IT for the North American Foods Division from 1993 to 1999. Prior to 1993, he held various positions in finance and was an internal auditor for International Multifoods Corporation from 1979 to 1981. Mr. Byom previously served on the board of MGP Ingredients Inc. Mr. Byom earned his B.A. in Accounting from Luther College.
|
| ||||||||||||
| | | | DIRECTOR QUALIFICATIONS: | | ||||||||||||
| | | |
|
| |
|
| |
|
| |
|
| |
|
|
|
Celeste A. Clark, Ph.D. Director
|
| ||||||||||||
|
|
| |
CAREER HIGHLIGHTS:
Celeste A. Clark, Ph.D. has served as a director since February 2021. Dr. Clark has been the principal of Abraham Clark Consulting, LLC, a consulting firm, since November 2011 and consults on nutrition and health policy, regulatory affairs and leadership development. Dr. Clark is also an adjunct professor in the Department of Food Science and Human Nutrition at Michigan State University since January 2012. She previously served as Senior Vice President, Global Policy and External Affairs of Kellogg Company, a food manufacturing company, and was the Chief Sustainability Officer until she retired in 2011. She was a member of the Global Executive Management Team and had an accomplished career spanning nearly 35 years at Kellogg Company in which time, she was responsible for the development and implementation of global health, nutrition and regulatory science initiatives. In addition, she led global corporate communications, public affairs, philanthropy and several administrative functions. Dr. Clark serves on the boards of The Hain Celestial Group, Inc. (organic and natural products) where she chairs the Compensation Committee, Wells Fargo & Company (financial services) where she chairs the Corporate Responsibility Committee and Darling Ingredients Inc. (sustainable products and renewable energy) where she serves as Chair of the ESG Committee. She also serves as a trustee of the W.K. Kellogg Foundation. Dr. Clark previously served on the boards of Mead Johnson Nutrition Company, Diamond Foods, Inc., AdvancePierre Foods Holdings, Inc., and Omega Protein Corporation. Dr. Clark received her Ph.D. from Michigan State University in Food Science and Nutrition and in 2021, she was bestowed an honorary Ph.D. in Humanities. She brings significant industry experience in various nutrition, consumer productions, public policy, risk management, governance, sustainability and ESG matters to the Board. Dr. Clark was recognized as a Director 100 by the National Association of Corporate Directors in 2023.
|
| |||||||||
| | | | DIRECTOR QUALIFICATIONS: | | |||||||||
| | | |
|
| |
|
| |
|
| |
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
24
|
|
|
James C. D’Arecca Director
|
| ||||||||||||
|
|
| |
CAREER HIGHLIGHTS:
James C. D’Arecca has served as a director since August 2023. Mr. D’Arecca is Executive Vice President, Chief Financial Officer of Haemonetics Corporation, a medical technology company, since April 2022 to present. Mr. D’Arecca previously served as Chief Financial Officer of TherapeuticsMD, Inc., a women’s healthcare company, from June 2020 to April 2022. Prior to joining TherapeuticsMD, Inc., Mr. D’Arecca served as the Senior Vice President and Chief Accounting Officer of Allergen plc (formerly known as Actavis plc), a global pharmaceutical company, from August 2013 until its merger with AbbVie Inc. in May 2020. Mr. D’Arecca served as Chief Accounting Officer at Bausch & Lomb prior to joining Actavis plc and earlier in his career held finance and business development positions of increasing responsibility at Merck & Co., Inc. and Schering-Plough Corporation. Mr. D’Arecca began his career at PricewaterhouseCoopers LLP from 1992 to 2005, where he had an industry focus on pharmaceuticals, medical devices, and consumer products.Mr. D’Arecca earned a Bachelor of Science in Accounting from Rutgers University and a Master of Business Administration from Columbia University. He is a Certified Public Accountant.
|
| |||||||||
| | | | DIRECTOR QUALIFICATIONS: | | |||||||||
| | | |
|
| |
|
| | | | |
|
Sheila A. Hopkins Director
|
| ||||||||||||
|
|
| |
CAREER HIGHLIGHTS:
Sheila A. Hopkins has served as a director since August 2015. Ms. Hopkins formerly served as the Interim Chief Executive Officer of Cutera, Inc., an energy based and aesthetic devices company, from April 2023 to August 2023. Previously she served as President, Global Vision Care and Executive Vice President of Bausch + Lomb, a healthcare company, from September 2011 until her retirement in August 2013. From September 1997 to August 2011, Ms. Hopkins worked at Colgate-Palmolive, a leading consumer products company, where she held several senior executive positions including Vice President and General Manager, Personal Care, Vice President, Global Business Development and Vice President and General Manager, Professional Oral Care. Prior to that, she held significant marketing and sales positions at Procter & Gamble, American Cyanamid and Tambrands. Ms. Hopkins previously served on the boards of Cutera, Inc. and Warnaco Inc. She has also served on the Board of the Consumer Healthcare Products Association. Ms. Hopkins earned a B.A. in History from Wellesley College
|
| |||||||||
| | | | DIRECTOR QUALIFICATIONS: | | |||||||||
| | | |
|
| |
|
| |
|
| |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
25
|
|
|
John F. Kelly Director
|
| ||||||||||||
|
|
| |
CAREER HIGHLIGHTS:
John F. Kelly was appointed to the Board in May 2024. Mr. Kelly retired in June 2022 after a 40-year career at Pfizer Inc., a biopharmaceutical company, where he was a member of the Pfizer Global Supply Leadership Team and a member of the Pfizer PAC Board of Directors. He held multiple positions in his career with Pfizer starting in August 1982 and finishing as the Vice President, Quality Operations and Environment, Health & Safety. At Pfizer, Mr. Kelly’s responsibilities included pharmaceutical and consumer product operations, manufacturing strategy, business development, quality and EHS. Between March 2019 and June 2022, he served as Chair of the Board of Directors of Zydus Cadila Oncology Private Limited, a 50/50 joint venture between Pfizer and Zydus Cadila, and prior to that he was a director of same between December 2015 and March 2019. Mr. Kelly is also Chair of the Board of Trustees of Wakeman Boys & Girls Club, and a member of the Worcester Polytechnic Institute Engineering Dean’s Advisory Board. Previously he was a member of the Board of Directors of The Patterson Club, Fairfield, CT and co-President of the Fairfield College Preparatory School Father’s Club. Mr. Kelly earned a degree in Chemical Engineering from Worcester Polytechnic Institute and an M.B.A in Operations Management from Pace University.
|
| |||||||||
| | | | DIRECTOR QUALIFICATIONS: | | |||||||||
| | | |
|
| |
|
| |
|
| |
|
Ronald M. Lombardi Chair of the Board, President and Chief Executive Officer
|
| ||||||||||||
|
|
| |
CAREER HIGHLIGHTS:
Ronald M. Lombardi was elected Chair of the Board in May 2017 and has served as a director and as President and Chief Executive Officer of the Company since June 2015. He served as Chief Financial Officer of the Company from December 2010 until November 2015. Prior to joining the Company, from October 2010 to December 2010, Mr. Lombardi was employed by Medtech Group Holdings, a components and contract medical device manufacturer, as Chief Financial Officer. From October 2009 to October 2010, Mr. Lombardi served as the Chief Financial Officer of Waterbury International Holdings, a specialty chemical and pest control business. Mr. Lombardi was employed by Cannondale Sports Group, a sporting goods and apparel manufacturing company, as Chief Operating Officer from August 2008 to October 2009 and as Senior Vice President and Chief Financial Officer from March 2004 to August 2008. From 2000 to 2004, Mr. Lombardi served in various roles at Gerber Scientific Inc., including Vice President and Chief Financial Officer of Gerber Scientific Inc.’s Gerber Coburn Optical Division and Director of Financial Planning and Analysis of Gerber Scientific Inc. Mr. Lombardi was also previously employed by Emerson Electric, Scovill Fasteners, Inc. and Go/Dan Industries. Mr. Lombardi serves on the board of ACCO Brands Corporation (consumer and business products), where he chairs the Audit Committee. Mr. Lombardi received a B.S. from Springfield College and an M.B.A. from American International College and has been a licensed CPA.
|
| |||||||||
| | | | DIRECTOR QUALIFICATIONS: | | |||||||||
| | | |
|
| |
|
| |
|
| |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
26
|
|
|
Dawn M. Zier Director
|
| |||||||||||||||
|
|
| |
CAREER HIGHLIGHTS:
Dawn M. Zier has served as a director since May 2020. Since February 2020, Ms. Zier has been the principal of Aurora Business Consulting, LLC and advises public and private companies on business transformation, digital/marketing acceleration, and high-performance teams. Ms. Zier is also a trusted advisor and mentor to Fortune 500 senior executives through her affiliation with The ExCo Group, a firm of experienced CEOs, board directors, and global leaders who bring real world experience to coaching and leadership development. Ms. Zier was formerly the President and CEO and a director of Nutrisystem, an innovative provider of weight loss programs and digital tools, from November 2012 until its March 2019 acquisition by Tivity Health, Inc., a leading provider of fitness and social engagement solutions. Ms. Zier then joined Tivity Health serving as President and Chief Operating Officer and a member of its Board of Directors, to help with the integration efforts through December 2019. Prior to November 2012, she served in a variety of executive positions at Reader’s Digest Association, a global media and data marketing company, including President of International from 2011-2012, President of Europe from 2009-2011, President of Global Consumer Marketing from 2008-2009 and President of North America Consumer Marketing from 2005-2008. Ms. Zier serves as Chair of the Board of The Hain Celestial Group, Inc. (organic and natural products). Ms. Zier has served on the boards of several other public companies and on the boards for multiple marketing and media entities, including the Data and Marketing Association’s (DMA) board from 2008 to 2015, where she was a voting director and on the executive committee. Ms. Zier earned her MBA and Master of Engineering from the Massachusetts Institute of Technology. Ms. Zier received her Corporate Director Certification from Harvard Business School in 2020 and was recognized as a Director 100 by the National Association of Corporate Directors in 2022.
|
| ||||||||||||
| | | | DIRECTOR QUALIFICATIONS: | | ||||||||||||
| | | |
|
| |
|
| |
|
| |
|
| |
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
27
|
|
|
POSITION
|
| |
2024 ANNUAL FEE($)
|
| |
INCREASE
|
| ||||||
|
•
Chair of the Audit and Finance Committee
|
| | | | 20,000 | | | | | | -0- | | |
|
•
Chair of the Compensation and Talent Management Committee
|
| | | | 20,000 | | | | | | 2,500 | | |
|
•
Chair of the Nominating and Corporate Governance Committee
|
| | | | 15,000 | | | | | | -0- | | |
|
•
Lead Independent Director
|
| | | | 30,000 | | | | | | -0- | | |
|
What does the Board of Directors recommend?
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
28
|
|
| | | |
2024
|
| |
2023
|
| ||||||
| Audit Fees | | | | $ | 1,652,902 | | | | | $ | 1,530,660 | | |
| Audit Related Fees | | | | | — | | | | | | 162,349 | | |
| Tax Fees | | | | | 162,231 | | | | | | 145,201 | | |
| All Other Fees | | | | | 3,143 | | | | | | 7,207 | | |
|
Total Independent Accountant’s Fees
|
| | | $ | 1,818,276 | | | | | $ | 1,845,417 | | |
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
29
|
|
|
WHAT DOES THE BOARD OF DIRECTORS RECOMMEND?
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
30
|
|
|
WHAT DOES THE BOARD RECOMMEND?
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
31
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
32
|
|
|
WHAT DOES THE BOARD RECOMMEND?
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
33
|
|
| | | |
Shares Beneficially Owned
|
| |||||||||
|
Name of Beneficial Owner
|
| |
Number
|
| |
Percentage(1)
|
| ||||||
| 5% or more Stockholders: | | | | | | | | | | | | | |
| BlackRock, Inc.(2) | | | | | 9,067,957 | | | | | | 18.3% | | |
| The Vanguard Group(3) | | | | | 5,756,138 | | | | | | 11.6% | | |
| Dimensional Fund Advisors LP(4) | | | | | 3,434,500 | | | | | | 6.9% | | |
| Macquarie Investment Management Business Trust(5) | | | | | 3,062,581 | | | | | | 6.2% | | |
| Ariel Investments, LLC(6) | | | | | 2,555,777 | | | | | | 5.2% | | |
| Directors and Named Executive Officers: | | | | | | | | | | | | | |
| Ronald M. Lombardi(7) | | | | | 419,967 | | | | | | * | | |
| Adel Mekhail(8) | | | | | 32,246 | | | | | | * | | |
| William C. P’Pool(9) | | | | | 49,684 | | | | | | * | | |
| Christine Sacco(10) | | | | | 102,059 | | | | | | * | | |
| Jeffrey Zerillo(11) | | | | | 59,384 | | | | | | * | | |
| John E. Byom | | | | | 48,003 | | | | | | * | | |
| Celeste A. Clark | | | | | 6,939 | | | | | | * | | |
| James C. D’Arecca | | | | | 0 | | | | | | * | | |
| Sheila A. Hopkins | | | | | 23,532 | | | | | | * | | |
| John F. Kelly | | | | | 0 | | | | | | * | | |
| Natale S. Ricciardi | | | | | 24,803 | | | | | | * | | |
| Dawn M. Zier | | | | | 9,942 | | | | | | * | | |
| All directors and executive officers as a group (12 persons)(12) | | | | | 776,559 | | | | | | 1.6% | | |
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
34
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
35
|
|
|
PLAN CATEGORY
|
| |
NUMBER OF
SECURITIES TO BE ISSUED UPON EXERCISE OF OUTSTANDING OPTIONS, WARRANTS AND RIGHTS (A) |
| |
WEIGHTED-
AVERAGE EXERCISE PRICE OF OUTSTANDING OPTIONS, WARRANTS AND RIGHTS (B) |
| |
NUMBER OF
SECURITIES REMAINING AVAILABLE FOR FUTURE ISSUANCE UNDER EQUITY COMPENSATION PLANS (EXCLUDING SECURITIES REFLECTED IN COLUMN (A)) (C) |
| |||||||||
| Equity compensation plans approved by security holders(1) | | | | | 1,450,625(2) | | | | | $ | 48.30(3) | | | | | | 1,880,001(4)(5) | | |
| Equity compensation plans not approved by security holders | | | | | — | | | | | | — | | | | | | — | | |
|
Total
|
| | | | 1,450,625 | | | | | $ | 48.30 | | | | | | 1,880,001 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
36
|
|
|
|
| | |
|
| | |
|
| | |
|
| | |
|
|
|
RONALD M.
LOMBARDI |
| | |
CHRISTINE
SACCO |
| | |
ADEL
MEKHAIL |
| | |
WILLIAM C.
P’POOL |
| | |
JEFFREY
ZERILLO |
|
|
President and Chief Executive Officer
|
| | |
Chief Financial Officer
|
| | |
Executive Vice President, Sales and Marketing
|
| | |
Senior Vice President, General Counsel and Corporate Secretary
|
| | |
Senior Vice President, Operations
|
|
|
STABLE REVENUE
|
| |
SUSTAINED
PROFITABILITY |
| |
STRONG FREE
CASH FLOW |
| |
LOW YEAR-END
LEVERAGE |
|
|
Stable Revenues of $1,125.4 Million
|
| |
Adjusted EPS
of $4.21 |
| |
Up 8% from 2023 to
$240 Million |
| |
2.8x Leverage
Lowest in Company History |
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
37
|
|
| COMPONENTS OF OUR COMPENSATION PROGRAM |
| |
ATTRACT,
RETAIN & MOTIVATE |
| |
SUPPORT
COMPANY OBJECTIVES |
| |
REINFORCE
STRATEGY |
| |
MAINTAIN GOOD
GOVERNANCE |
|
|
Base Salary
|
| |
|
| | | | | | | |
|
|
|
Annual Cash Incentive Awards
|
| |
|
| |
|
| |
|
| |
|
|
|
Long-term Equity Awards
|
| |
|
| |
|
| |
|
| |
|
|
|
GOALS OF THE PROGRAM:
|
| |||
|
■
To attract, retain and motivate talented management taking competitors’ compensation practices into account;
■
Reinforce our strategy; and
|
| |
■
To support achievement of our Company-wide objectives and increase stockholder value;
■
Maintain practices that support good governance.
|
|
|
ANNUAL CASH INCENTIVE AWARDS:
|
|
|
■
Our named executive officers earned their annual cash incentive awards through our Annual Incentive Plan (“AIP”) primarily based on the Company’s achievement of pre-determined performance goals related to net sales (weighted 50%) and Adjusted AIP EBITDA (weighted 50%), as defined later in the Compensation Discussion and Analysis.
■
The Company came within 99% of its net sales target and 97% of its Adjusted EBITDA goals in the very challenging macroeconomic environment.
■
Pursuant to the 2024 AIP, our named executive officers achieved a bonus payout equal to 88% of their target bonus based on the financial performance of the Company. Our plan also allows for an individual adjustment, up or down, based on individual performance as discussed later in Compensation Discussion and Analysis.
|
|
|
LONG-TERM INCENTIVE AWARDS
|
|
|
■
The performance-based orientation of our long-term incentive program is reflected in 75% of our CEO’s targeted value of the long-term incentive award allocated to performance stock units, which are earned based on performance over 3-years. The remaining 25% is delivered in restricted stock units, which ratably vest over 3-years.
■
Our other named executive officers’ targeted value of the long-term incentive award was allocated 60% to performance stock units and 40% to restricted stock units.
■
Challenging 3-year goals are set for adjusted cumulative revenue and cumulative EBITDA metrics.
■
The May 2021 performance stock unit grant payout was 153.2% for the three-year performance period, fiscal 2022 through 2024.
|
|
|
DYNAMIC ENVIRONMENT
|
|
|
■
During fiscal 2024 we generated stable revenues and earnings even within the backdrop of a dynamic economic environment with significant supply chain challenges and high inflation. Consistent with our long-term strategy, we reduced net leverage to the lowest point in Company history providing enhanced capital allocation optionality for the future. This record performance demonstrates that our business strategy and diversified portfolio of consumer healthcare brands gives us the ability to generate outstanding value across economic environments.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
38
|
|
|
The Committee is composed solely of independent directors.
The Committee’s independent compensation consultant, CAP, is retained directly by the Compensation and Talent Management Committee and performs no other consulting or other services for us.
|
| | |
The Committee conducts an annual review of our compensation-related risk profile to ensure that compensation-related risks are not reasonably likely to have a material adverse effect on the Company.
The Committee regularly reviews succession and talent management.
|
|
|
No evergreen provision. The Company’s 2020 Long-Term Incentive Plan (“2020 LTIP”) does not contain an “evergreen” feature pursuant to which the shares authorized for issuance under the 2020 LTIP can be automatically replenished.
No repricing of stock options. Without the prior approval of the Company’s stockholders, outstanding stock options cannot be repriced, directly or indirectly, nor may stock options be cancelled in exchanged for stock options with an exercise price that is less than the exercise price of the original stock options. In addition, the Company may not, without the prior approval of stockholders, repurchase an option for value from a participant if the current market value of the underlying stock is lower than the exercise price per share of the option.
Clawback Policy. All awards (and/or any amount received with respect to such awards) under the Annual Incentive Plan and the 2020 LTIP are subject to reduction, cancellation, forfeiture or recoupment to the extent necessary to comply with applicable law, stock exchange listing requirements, and the recoupment policy of the Company.
Minimum vesting requirements. Awards granted under the 2020 LTIP will be subject to a minimum vesting period of one year except for 5% of the pool that is available to grant with shorter vesting.
No dividends on unearned awards. The 2020 LTIP prohibits the current payment of dividends or dividend equivalent rights on unearned awards.
No Excessive Perqs. We do not provide excessive perquisites.
|
| | |
No liberal share recycling provisions. Shares retained by or delivered to the Company to pay the exercise price of a stock option or to satisfy tax withholding obligations in connection with the exercise, vesting or settlement of an award count against the number of shares remaining available under the 2020 LTIP.
No single-trigger change of control vesting. If awards granted under the 2020 LTIP are assumed by the successor entity in connection with a change of control of the Company, such awards will not automatically vest and pay out upon the change of control.
Limitation on non-employee director compensation. The 2020 LTIP provides that, with respect to any one fiscal year, the aggregate compensation that may be granted or awarded to any one non-employee director, including all stock awards and cash payments shall not exceed $600,000,or $900,000 in the case of a non- employee Chair of the Board or Lead Director.
No Gross-Ups. Our executive severance plan does not contain a Section 280G excise tax “gross-up” provision.
Robust Stock Ownership Guidelines. We maintain robust stock ownership guidelines for both officers and directors, which are described later in this CD&A.
No Hedging. We prohibit hedging and limit pledging by the Company’s directors, executive officers and employees.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
39
|
|
| | | | | |
|
2023 Say on pay
approval |
| |
Yes. At the 2023 Annual Meeting of Stockholders, approximately 95% of the shares represented, entitled to vote and voted at the annual meeting were voted to approve the compensation of the Company’s named executive officers as discussed and disclosed in our 2023 Proxy Statement. In considering the results of this advisory vote on executive compensation, the Compensation and Talent Management Committee concluded that the compensation paid to our named executive officers and the Company’s overall compensation program enjoy strong stockholder support. We also regularly meet with our largest stockholders and solicit feedback on a wide range of topics.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
40
|
|
|
■
motivate our business leaders to deliver a high degree of business performance and ensure that their interests are closely aligned with those of our stockholders;
|
| | | | |
■
attract and retain highly qualified senior leaders who can drive a successful global enterprise in today’s competitive marketplace and represent the diversity of our employees and the customers we serve;
|
| | | | |
■
establish executive compensation that is competitive with the compensation offered by similarly situated companies;
|
|
| | | | | | | | | | | | | | |
|
■
focus management on both the Company’s short-term and long-term strategy, performance and success;
|
| | | | |
■
maintain practices that support good governance; and
|
| | | | |
■
structure programs that mitigate any incentives to take excessive risks.
|
|
|
■
the executive’s level of responsibility and function within the Company;
|
| | | | |
■
the overall performance and profitability of the Company;
|
| | | | |
■
the executive’s performance within the Company;
|
|
|
■
executive compensation offered to similarly situated executives at peer companies; and
|
| | | | |
■
good governance practices.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
41
|
|
|
LONG-TERM INCENTIVE (LTI) VEHICLE
|
| |
TARGET LTI NEOS
OTHER THAN CEO |
| |
TARGET LTI
VALUE CEO |
| ||||||
| Performance Stock Units | | | | | 60% | | | | | | 75% | | |
| Service-based Restricted Stock Units | | | | | 40% | | | | | | 25% | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
42
|
|
|
2024 PEER GROUP
|
| |||
|
■
B&G Foods Holdings Corp.
|
| |
■
Calavo Growers Inc.
|
|
|
■
Church & Dwight Co.
|
| |
■
Edgewell Personal Care Company
|
|
|
■
Energizer Holdings, Inc.
|
| |
■
Hain Celestial Group, Inc.
|
|
|
■
Helen of Troy Limited
|
| |
■
Jazz Pharmaceuticals plc
|
|
|
■
Hostess Brands, Inc.
|
| |
■
Primo Water Corporation
|
|
|
■
Tupperware Brands Corp
|
| |
■
Vista Outdoor Inc.
|
|
|
■
USANA Health Sciences, Inc.
|
| |
■
Corcept Therapeutics Incorporated
|
|
|
■
Pacira BioSciences, Inc.
|
| |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
43
|
|
|
NAME
|
| |
2024 SALARY
|
| |
2025 SALARY
|
| |
% INCREASE
EFFECTIVE APRIL 1, 2024* |
| ||||||
| Mr. Lombardi | | | | $ | 1,000,000 | | | | | $ | 1,000,000 | | | |
0%
|
|
| Ms. Sacco | | | | $ | 625,000 | | | | | $ | 645,000 | | | |
3.2%
|
|
| Mr. Mekhail | | | | $ | 515,000 | | | | | $ | 528,000 | | | |
2.5%
|
|
| Mr. P’Pool | | | | $ | 530,000 | | | | | $ | 546,000 | | | |
3%
|
|
| Mr. Zerillo | | | | $ | 360,000 | | | | | $ | 370,000 | | | |
2.8%
|
|
|
METRIC
|
| |
WEIGHTING
|
| |
DEFINITION
|
| |
RATIONALE FOR SELECTION
|
|
|
AIP net sales
|
| |
|
| |
Total revenues.
|
| |
Drive consistent top-line growth.
|
|
|
AIP Adjusted EBITDA
|
| |
|
| |
Net income plus depreciation and amortization, interest expense, integration, transition, purchase accounting, legal and various other costs associated with acquisitions and divestitures, tradename impairment and certain tax adjustments.
|
| |
Drive stockholder value creation in terms of growth of earnings per share and free cash flow.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
44
|
|
| | | | | | | | | |
PERFORMANCE LEVEL/ PAYOUT (MIL)
|
| |||||||||||||||
|
METRIC
|
| |
WEIGHTING
|
| |
THRESHOLD
(50%) |
| |
TARGET
(100%) |
| |
MAXIMUM
(200%) |
| ||||||||||||
| AIP net sales | | | | | 50% | | | | | $ | 1,028.3 | | | | | $ | 1,142.6 | | | | | $ | 1,256.9 | | |
| AIP Adjusted EBITDA | | | | | 50% | | | | | $ | 348.0 | | | | | $ | 386.7 | | | | | $ | 425.4 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
45
|
|
|
NAME
|
| |
TARGET BONUS
|
| |
COMPANY
PERFORMANCE PAYOUT (88% OF TARGET BONUS) |
| |
INDIVIDUAL
PERFORMANCE ADJUSTMENT |
| |
TOTAL PAYOUT
|
| ||||||||||||
| Mr. Lombardi | | | | $ | 1,150,000 | | | | | $ | 1,012,000 | | | | | $ | 0 | | | | | $ | 1,012,000 | | |
| Ms. Sacco | | | | $ | 375,000 | | | | | $ | 330,000 | | | | | $ | 0 | | | | | $ | 330,000 | | |
| Mr. Mekhail | | | | $ | 309,000 | | | | | $ | 271,920 | | | | | $ | 0 | | | | | $ | 271,920 | | |
| Mr. P’Pool | | | | $ | 265,000 | | | | | $ | 233,200 | | | | | $ | 23,320 | | | | | $ | 256,520 | | |
| Mr. Zerillo | | | | $ | 144,000 | | | | | $ | 126,720 | | | | | $ | 0 | | | | | $ | 126,720 | | |
|
■
the use of multi-year vesting for equity awards encourages executive retention and emphasizes the attainment of long-term performance goals;
|
| | | | |
■
paying a significant portion of executive compensation with long-term incentive-based compensation motivates and incentivizes the executive officers to meet the long-term performance goals set by the Compensation and Talent Management Committee; and
|
| | | | |
■
the executive officers will hold significant amounts of equity in the Company as required by the Company’s Stock Ownership Guidelines and will be motivated to increase stockholder value over the long-term.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
46
|
|
|
NAME
|
| |
FY2024 TARGETED
AWARD VALUE |
| |
% INCREASE
FROM FY2023 |
| ||||||
| Mr. Lombardi | | | | $ | 3,700,000 | | | | | | 2.8 | | |
| Ms. Sacco | | | | $ | 1,030,000 | | | | | | 3.0 | | |
| Mr. Mekhail | | | | $ | 515,000 | | | | | | 3.0 | | |
| Mr. P’Pool | | | | $ | 540,000 | | | | | | 3.7 | | |
| Mr. Zerillo | | | | $ | 360,000 | | | | | | 2.9 | | |
|
Performance Stock Units
|
| |
■
Vest at the end of three years if company achieves pre-established goals relative to cumulative adjusted EBITDA and cumulative Net Sales (each weighted 50%).
■
The actual payout is determined based on the Company’s actual performance aggregated over the three-year period on a sliding-scale between the minimum (threshold) amount and the maximum amount, inclusive of the target amount.
■
Participants can earn up to 200% of the target number of shares with exceptional performance.
■
If performance is below target, but above threshold, participants can earn 50% of their award.
■
If performance is below threshold, participants earn 0% of their award.
|
|
|
Restricted Stock Units
|
| |
Vest ratably over three years based on service.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
47
|
|
|
METRIC
|
| |
WEIGHTING
|
| |
DEFINITION
|
| |
RATIONALE FOR
SELECTION |
|
| Cumulative Net Sales | | | 50% | | | The Company’s cumulative annual ”Net Sales,” as reported in the Company’s audited financial statements for the 3-year performance period, adjusted to exclude divestitures, acquisitions, changes in accounting policy and other adjustments deemed appropriate by the Committee. | | | Drive consistent top-line growth over time | |
| Cumulative EBITDA | | | 50% | | | Company’s cumulative reported net earnings (loss) excluding earnings (loss) from discontinued operations, net of the provision (benefit) for income taxes, net of interest income and expense, net of depreciation and amortization. EBITDA for the 3-year performance period is adjusted to exclude divestitures, acquisitions, costs associated with integration, transition, purchase accounting, impairment charges, changes in accounting policy and other adjustments deemed appropriate by the Committee. | | | Drive stockholder value creation in terms of growth of earnings per share and free cash flow. | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
48
|
|
| | | |
RESULTS
|
| |
TARGET
|
| ||||||
| 3-Year Cumulative Sales | | | | $ | 3,339.9 | | | | | $ | 3,117.5 | | |
| 3-Year Cumulative EBITDA | | | | $ | 1,119.6 | | | | | $ | 1,082.0 | | |
|
Performance Multiplier 153.2%
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
49
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
50
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
51
|
|
|
Ronald M. Lombardi Chair of the Board, President and Chief Executive Officer
|
| |
Age: 60
|
| |||
|
|
| |
CAREER HIGHLIGHTS:
Ronald M. Lombardi was elected Chair of the Board in May 2017 and has served as a director and as President and Chief Executive Officer of the Company since June 2015. He served as Chief Financial Officer of the Company from December 2010 until November 2015. Prior to joining the Company, from October 2010 to December 2010, Mr. Lombardi was employed by Medtech Group Holdings, a components and contract medical device manufacturer, as Chief Financial Officer. From October 2009 to October 2010, Mr. Lombardi served as the Chief Financial Officer of Waterbury International Holdings, a specialty chemical and pest control business. Mr. Lombardi was employed by Cannondale Sports Group, a sporting goods and apparel manufacturing company, as Chief Operating Officer from August 2008 to October 2009 and as Senior Vice President and Chief Financial Officer from March 2004 to August 2008. From 2000 to 2004, Mr. Lombardi served in various roles at Gerber Scientific Inc., including Vice President and Chief Financial Officer of Gerber Scientific Inc.’s Gerber Coburn Optical Division and Director of Financial Planning and Analysis of Gerber Scientific Inc. Mr. Lombardi was also previously employed by Emerson Electric, Scovill Fasteners, Inc. and Go/Dan Industries. Mr. Lombardi currently serves as Chair of the Audit Committee on the board of ACCO Brands Corporation. Mr. Lombardi received a B.S. from Springfield College and an M.B.A. from American International College and has been a licensed CPA.
|
|
|
Christine Sacco Chief Financial Officer
|
| |
Age: 49
|
| |||
|
|
| |
CAREER HIGHLIGHTS:
Christine Sacco was appointed to the position of Chief Financial Officer for the Company in September 2016. Ms. Sacco joined the Company from Boulder Brands, Inc., a health and wellness food manufacturer, where she served as the Chief Financial Officer and Treasurer from January 2012 to January 2016 and Vice President and Controller from January 2008 to January 2012, including Principal Accounting Officer from January 2011 to March 2012. From October 2002 until January 2008, she held positions of increasing financial responsibility with Alpharma, Inc., a global specialty pharma company, where she last held the position of Vice President, Treasurer. Ms. Sacco began her career with Ernst & Young and worked for five years in the Audit and Assurance group. She holds a B.S. in accounting from St. Thomas Aquinas College and has been a licensed CPA.
|
|
|
William C. P’Pool Senior Vice President, General Counsel and Corporate Secretary
|
| |
Age: 58
|
| |||
|
|
| |
CAREER HIGHLIGHTS:
William C. P’Pool was appointed to the position of Senior Vice President, General Counsel and Corporate Secretary for the Company in November 2016. From June 2004 to April 2015, Mr. P’Pool served in progressive leadership roles at Mead Johnson Nutrition Company, a nutritional products company, the last being Senior Vice President, General Counsel and Corporate Secretary. From May 2001 to June 2004, Mr. P’Pool served as a Senior Counsel and Director of Legal Services at Yum! Brands, Inc. From 1991 to 2001, he served in legal roles of increasing responsibility at GrafTech International and Service Merchandise Company, among others. He earned a B.S. in business from Murray State University and a J.D. from the University of Kentucky.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
52
|
|
|
Adel Mekhail Executive Vice President, Marketing & Sales
|
| |
Age: 63
|
| |||
|
|
| |
CAREER HIGHLIGHTS:
Adel Mekhail was appointed to the position of Executive Vice President of Marketing & Sales for the Company in May 2019. From April 2017 to July 2018, Mr. Mekhail served as Vice President, Americas at Edgewell Personal Care Company, a personal care products company, and from July 2015 to April 2017 he served as Vice President and General Manager, Private Brands Group and Vice President, Latin America. From November 2013 to July 2015, Mr. Mekhail served as Vice President, Asia Pacific at Energizer. He held other increasingly responsible marketing roles at Energizer from 2003 to 2013. Mr. Mekhail also served in sales and marketing roles for Pfizer and Warner Lambert from 1996 to 2003. In 2000, he moved from Australia to the United States for Pfizer. Mr. Mekhail earned his BS in Pharmaceutical Sciences from Tanta University in Egypt and his MBA from RMIT University in Melbourne, Australia.
|
|
|
Jeffrey Zerillo Executive Vice President, Operations
|
| |
Age: 63
|
| |||
|
|
| |
CAREER HIGHLIGHTS:
Jeffrey Zerillo was appointed to the position of Senior Vice President, Operations for the Company in April 2018. Mr. Zerillo joined the Company from Teva Pharmaceuticals, a pharmaceutical company, where he served as Vice President, Supply Chain Management for the America’s Region from 2016 to 2018. He brings experience managing complex supply chains in pharmaceuticals, biologics and medical devices from companies including Actavis/Allergan, a pharmaceutical company, from 2014 to 2016, Purdue Pharma from 1995 to 2013, Tura L.P. from 1994 to 1995 and Instrumentation Laboratories from 1988 to 1994. He earned a B.S. in Business Management- Production Operations from York College of Pennsylvania and an Executive Certificate from Sloan School of Business.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
53
|
|
|
NAME AND PRINCIPAL POSITION
|
| |
FISCAL
YEAR |
| |
SALARY
($) |
| |
BONUS
($) |
| |
STOCK
AWARDS ($)(1) |
| |
OPTION
AWARDS ($)(2) |
| |
NON-EQUITY
INCENTIVE PLAN COMPENSATION ($)(3) |
| |
ALL OTHER
COMPENSATION ($) |
| |
TOTAL
($) |
| |||||||||||||||||||||
|
Ronald M. Lombardi
Chair, President, and Chief Executive Officer |
| | | | 2024 | | | | | | 1,002,632 | | | | | | | | | 3,700,034 | | | | | | 0 | | | | | | 1,012,000 | | | | | | 48,467(4) | | | | | | 5,763,133 | | |
| | | 2023 | | | | | | 1,002,322 | | | | | | | | | 3,600,031 | | | | | | 0 | | | | | | 934,000 | | | | | | 46,756(4) | | | | | | 5,583,109 | | | |||
| | | 2022 | | | | | | 937,321 | | | | | | | | | 3,299,970 | | | | | | 0 | | | | | | 1,750,000 | | | | | | 44,226(4) | | | | | | 6,031,517 | | | |||
|
Christine Sacco
Chief Financial Officer |
| | | | 2024 | | | | | | 625,809 | | | | | | | | | 1,029,965 | | | | | | 0 | | | | | | 330,000 | | | | | | 15,075(5) | | | | | | 2,000,849 | | |
| | | 2023 | | | | | | 605,809 | | | | | | | | | 666,712 | | | | | | 333,327 | | | | | | 339,042 | | | | | | 14,062(5) | | | | | | 1,958,952 | | | |||
| | | 2022 | | | | | | 565,809 | | | | | | | | | 633,298 | | | | | | 316,669 | | | | | | 682,410 | | | | | | 13,219(5) | | | | | | 2,211,405 | | | |||
|
Adel Mekhail
Executive Vice President, Sales and Marketing |
| | | | 2024 | | | | | | 516,583 | | | | | | | | | 515,013 | | | | | | 0 | | | | | | 271,920 | | | | | | 15,018(5) | | | | | | 1,318,534 | | |
| | | 2023 | | | | | | 503,543 | | | | | | | | | 333,356 | | | | | | 166,663 | | | | | | 280,200 | | | | | | 14,197(5) | | | | | | 1,297,959 | | | |||
| | | 2022 | | | | | | 473,308 | | | | | | | | | 316,694 | | | | | | 158,335 | | | | | | 485,040 | | | | | | 13,117(5) | | | | | | 1,446,494 | | | |||
|
William C. P’Pool
Senior Vice President, General Counsel and |
| | | | 2024 | | | | | | 532,321 | | | | | | | | | 540,014 | | | | | | 0 | | | | | | 256,520 | | | | | | 15,030(5) | | | | | | 1,343,885 | | |
| | | 2023 | | | | | | 516,314 | | | | | | | | | 346,647 | | | | | | 173,324 | | | | | | 240,038 | | | | | | 13,623(5) | | | | | | 1,289,946 | | | |||
| | | 2022 | | | | | | 485,226 | | | | | | | | | 332,032 | | | | | | 166,002 | | | | | | 456,918 | | | | | | 13,196(5) | | | | | | 1,453,374 | | | |||
|
Jeffrey Zerillo
Senior Vice President, Operations |
| | | | 2024 | | | | | | 362,448 | | | | | | | | | 360,009 | | | | | | 0 | | | | | | 126,720 | | | | | | 13,750(5) | | | | | | 862,927 | | |
| | | 2023 | | | | | | 352,365 | | | | | | | | | 233,349 | | | | | | 116,663 | | | | | | 130,760 | | | | | | 13,781(5) | | | | | | 846,918 | | | |||
| | | 2022 | | | | | | 337,248 | | | | | | | | | 225,374 | | | | | | 112,661 | | | | | | 230,480 | | | | | | 13,156(5) | | | | | | 918,885 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
54
|
|
| | | | | | | | | |
ESTIMATED FUTURE PAYOUTS UNDER
NON-EQUITY INCENTIVE PLAN AWARDS(1) |
| |
ESTIMATED FUTURE PAYOUTS
UNDER EQUITY INCENTIVE PLAN AWARDS(2) |
| |
ALL OTHER
STOCK AWARDS: NUMBER OF SHARES OR STOCK UNITS (#)(3) |
| |
GRANT
DATE FAIR VALUE OF STOCK AWARDS ($)(4) |
| ||||||||||||||||||||||||||||||||||||
|
NAME
|
| |
GRANT DATE
|
| |
THRESHOLD
($) |
| |
TARGET
($) |
| |
MAXIMUM
($) |
| |
THRESHOLD
(#) |
| |
TARGET
(#) |
| |
MAXIMUM
(#) |
| |||||||||||||||||||||||||||||||||
|
Mr. Lombardi
|
| | | | | | | | | | 575,000 | | | | | | 1,150,000 | | | | | | 2,300,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 14,985 | | | | | | 925,024 | | | |||
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | 22,477 | | | | | | 44,954 | | | | | | 89,908 | | | | | | | | | | | | 2,775,010 | | | |||
|
Ms. Sacco
|
| | | | | | | | | | 187,500 | | | | | | 375,000 | | | | | | 750,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,674 | | | | | | 411,986 | | | |||
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | 5,006 | | | | | | 10,011 | | | | | | 20,022 | | | | | | | | | | | | 617,979 | | | |||
|
Mr. Mekhail
|
| | | | | | | | | | 154,500 | | | | | | 309,000 | | | | | | 618,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,337 | | | | | | 205,993 | | | |||
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | 2,503 | | | | | | 5,006 | | | | | | 10,012 | | | | | | | | | | | | 309,020 | | | |||
|
Mr. P’Pool
|
| | | | | | | | | | 132,500 | | | | | | 265,000 | | | | | | 530,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,499 | | | | | | 215,993 | | | |||
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | 2,625 | | | | | | 5,249 | | | | | | 10,498 | | | | | | | | | | | | 324,020 | | | |||
|
Mr. Zerillo
|
| | | | | | | | | | 72,000 | | | | | | 144,000 | | | | | | 288,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,333 | | | | | | 144,016 | | | |||
| | | 5/2/2023 | | | | | | | | | | | | | | | | | | | | | | | | 1,749 | | | | | | 3,499 | | | | | | 6,998 | | | | | | | | | | | | 215,993 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
55
|
|
| | | |
OPTION AWARDS
|
| |
STOCK AWARDS
|
| ||||||||||||||||||||||||||||||||||||||||||
|
NAME
|
| |
NUMBER OF
SECURITIES UNDERLYING UNEXERCISED OPTIONS (#) EXERCISABLE |
| |
NUMBER OF
SECURITIES UNDERLYING UNEXERCISED OPTIONS (#) UNEXERCISABLE |
| |
OPTION
EXERCISE PRICE ($) |
| |
OPTION
EXPIRATION DATE |
| |
NUMBER OF
SHARES OR UNITS OF STOCK THAT HAVE NOT VESTED (#) |
| |
MARKET
VALUE OF SHARES OR UNITS OF STOCK THAT HAVE NOT VESTED(1) ($) |
| |
EQUITY
INCENTIVE PLAN AWARDS: NUMBER OF UNEARNED SHARES, UNITS OR OTHER RIGHTS THAT HAVE NOT VESTED (#) |
| |
EQUITY INCENTIVE
PLAN AWARDS: MARKET OR PAYOUT VALUE OF UNEARNED SHARES, UNITS OR OTHER RIGHTS THAT HAVE NOT VESTED(1) ($) |
| ||||||||||||||||||||||||
|
Mr. Lombardi
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 14,985(11) | | | | | | 1,087,312 | | | | | | 44,954(14) | | | | | | 3,261,862 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | 11,016(10) | | | | | | 799,321 | | | | | | 49,569(13) | | | | | | 3,596,727 | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 6,204(9) | | | | | | 450,162 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 85,533(12) | | | | | | 6,206,274 | | | | | | | | | | | | | | | |||
| | | 39,387(3) | | | | | | 0(3) | | | | | | 56.11 | | | | | | 5/8/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 53,725(2) | | | | | | 0(2) | | | | | | 57.18 | | | | | | 5/9/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
|
Ms. Sacco
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,674(11) | | | | | | 484,265 | | | | | | 10,011(14) | | | | | | 726,398 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | 10,943(12) | | | | | | 794,024 | | | | | | | | | | | | | | | |||
| | | 5,683(8) | | | | | | 11,367(8) | | | | | | 54.47 | | | | | | 5/2/2032 | | | | | | 4,080(10) | | | | | | 296,045 | | | | | | 6,120(13) | | | | | | 444,067 | | | |||
| | | 14,620(7) | | | | | | 7,310(7) | | | | | | 44.33 | | | | | | 5/3/2031 | | | | | | 2,381(9) | | | | | | 172,765 | | | | | | | | | | | | | | | |||
| | | 20,604(6) | | | | | | 0(6) | | | | | | 39.98 | | | | | | 5/4/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 24,686(5) | | | | | | 0(5) | | | | | | 30.56 | | | | | | 5/6/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
|
Mr. Mekhail
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,337(11) | | | | | | 242,133 | | | | | | 5,006(14) | | | | | | 363,235 | | |
| | | 2,841(8) | | | | | | 5,684(8) | | | | | | 54.47 | | | | | | 5/2/2032 | | | | | | 2,040(10) | | | | | | 148,022 | | | | | | 3,060(13) | | | | | | 222,034 | | | |||
| | | 7,310(7) | | | | | | 3,655(7) | | | | | | 44.33 | | | | | | 5/3/2031 | | | | | | 1,191(9) | | | | | | 86,419 | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 5,472(12) | | | | | | 397,048 | | | | | | | | | | | | | | | |||
|
Mr. P’Pool
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,499(11) | | | | | | 253,887 | | | | | | 5,249(14) | | | | | | 380,867 | | |
| | | 2,731(8) | | | | | | 5,464(8) | | | | | | 54.47 | | | | | | 5/2/2032 | | | | | | 2,122(10) | | | | | | 153,972 | | | | | | 3,182(13) | | | | | | 230,886 | | | |||
| | | 7,664(7) | | | | | | 3,832(7) | | | | | | 44.33 | | | | | | 5/3/2031 | | | | | | 1,249(9) | | | | | | 90,627 | | | | | | | | | | | | | | | |||
| | | 6,333(3) | | | | | | 0(3) | | | | | | 56.11 | | | | | | 5/8/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 5,737(12) | | | | | | 416,277 | | | | | | | | | | | | | | | |||
|
Mr. Zerillo
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,333(11) | | | | | | 169,282 | | | | | | 3,499(14) | | | | | | 253,887 | | |
| | | 1,838(8) | | | | | | 3,678(8) | | | | | | 54.47 | | | | | | 5/2/2032 | | | | | | 1,428(10) | | | | | | 103,616 | | | | | | 2,142(13) | | | | | | 155,424 | | | |||
| | | 5,201(7) | | | | | | 2,601(7) | | | | | | 44.33 | | | | | | 5/3/2031 | | | | | | 848(9) | | | | | | 61,531 | | | | | | | | | | | | | | | |||
| | | 8,399(6) | | | | | | 0(6) | | | | | | 39.98 | | | | | | 5/4/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 10,063(5) | | | | | | 0(5) | | | | | | 30.56 | | | | | | 5/6/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 10,078(4) | | | | | | 0(4) | | | | | | 29.46 | | | | | | 5/7/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 3,894(12) | | | | | | 282,549 | | | | | | | | | | | | | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
56
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
57
|
|
| | | |
OPTION AWARDS
|
| |
STOCK AWARDS
|
| ||||||||||||||||||
|
NAME
|
| |
NUMBER OF
SHARES ACQUIRED ON EXERCISE (#) |
| |
VALUE REALIZED
ON EXERCISE ($)(1) |
| |
NUMBER OF
SHARES ACQUIRED ON VESTING (#) |
| |
VALUE REALIZED
ON VESTING ($)(2) |
| ||||||||||||
| Mr. Lombardi | | | | | 32,800 | | | | | | 1,036,040 | | | | | | 105,974 | | | | | | 6,566,134 | | |
| Ms. Sacco | | | | | 61,817 | | | | | | 1,303,811 | | | | | | 16,571 | | | | | | 1,025,308 | | |
| Mr. Mekhail | | | | | 32,743 | | | | | | 1,006,944 | | | | | | 9,021 | | | | | | 558,270 | | |
| Mr. P’Pool | | | | | 26,019 | | | | | | 581,027 | | | | | | 9,582 | | | | | | 593,007 | | |
| Mr. Zerillo | | | | | 0 | | | | | | 0 | | | | | | 6,514 | | | | | | 403,139 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
58
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
59
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
60
|
|
|
NAME
|
| |
TERMINATION BY
COMPANY WITHOUT CAUSE OR RESIGNATION WITH GOOD REASON ($)(1) |
| |
DEATH/
DISABILITY ($)(2) |
| |
QUALIFYING
TERMINATION IN CONNECTION WITH CHANGE IN CONTROL ($)(3) |
| |||||||||
| Mr. Lombardi | | | | $ | 3,251,133 | | | | | $ | 13,246,481 | | | | | $ | 18,656,326 | | |
| Ms. Sacco | | | | $ | 1,017,157 | | | | | $ | 3,053,827 | | | | | $ | 5,088,141 | | |
| Mr. Mekhail | | | | $ | 850,275 | | | | | $ | 1,527,032 | | | | | $ | 3,227,581 | | |
| Mr. P’Pool | | | | $ | 823,414 | | | | | $ | 1,588,999 | | | | | $ | 3,235,828 | | |
| Mr. Zerillo | | | | $ | 522,629 | | | | | $ | 1,068,149 | | | | | $ | 2,113,406 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
61
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
62
|
|
| Year | | | Summary Compensation Table Total for CEO(1) | | | Compensation Actually Paid to CEO(2) | | | Average Summary Compensation Table Total for non-CEO NEOs(1)(3) | | | Average Compensation Actually Paid to non-CEO NEOs(2)(3) | | | Value of Initial Fixed $100 Investment Based on: | | | Net Income (in millions)(6) | | | Adjusted EBITDA (in millions)(7) | | |||||||||||||||||||||||||||
| Total Shareholder Return(4) | | | Peer Group Total Shareholder Return(4)(5) | | |||||||||||||||||||||||||||||||||||||||||||||
| 2024 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||||
| 2023 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | -$ | | | | | $ | | | ||||||||
| 2022 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||||
| 2021 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
63
|
|
| Reconciliation of Summary Compensation Totals and Compensation Actually Paid | | | 2024 | | | 2023 | | | 2022 | | | 2021 | | |||||||||||||||||||||||||||||||||||||||
| CEO | | | Average Non-CEO NEOs | | | CEO | | | Average Non-CEO NEOs | | | CEO | | | Average Non-CEO NEOs | | | CEO | | | Average Non-CEO NEOs | | ||||||||||||||||||||||||||||||
| Summary Compensation Table Total | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | |||||||||||
| - Stock and Option Awards(a) | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | |||||||||||
| Equity Award Adjustments(b) | | | + Year End Fair Value of Equity Awards Granted in the Applicable Year | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||||
| + Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that are Unvested at Year End | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | |||||||||||
| + Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | | | | -$ | | | | | -$ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | |||||||||||
| Compensation Actually Paid | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | |
| | | | Most Important | | | | |
| | | | Performance Measures | | | | |
| | | | > | | | | |
| | | | > | | | | |
| | | | > | | | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
64
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
65
|
|
|
NAME
|
| |
FEES EARNED OR
PAID IN CASH ($) |
| |
STOCK AWARDS
($)(1) |
| |
TOTAL
($) |
| |||||||||
| Mr. Byom | | | | | 123,333 | | | | | | 150,000 | | | | | | 273,333 | | |
| Ms. Clark | | | | | 107,083 | | | | | | 150,000 | | | | | | 257,083 | | |
| Mr. D’Arecca | | | | | 47,916 | | | | | | 150,000 | | | | | | 197,916 | | |
| Ms. Hopkins | | | | | 93,333 | | | | | | 150,000 | | | | | | 243,333 | | |
| Mr. Ricciardi | | | | | 93,333 | | | | | | 150,000 | | | | | | 243,333 | | |
| Ms. Zier | | | | | 110,625 | | | | | | 150,000 | | | | | | 260,625 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
66
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
67
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
68
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
69
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
70
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
71
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
72
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
73
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
74
|
|
|
PROPOSAL
|
| | BOARD’S RECOMMENDATION |
| |
SEE
PAGE |
| |||||||||||||||
|
1
|
| |
To elect the seven directors nominated by the Board of Directors and named in this Proxy Statement to serve until the 2025 Annual Meeting of Stockholders or until their earlier death, removal or resignation
|
| |
|
| |
FOR each director nominee
|
| |
19
|
| |||||||||
| | | |
☐
Ronald M.
Lombardi
|
| |
☐
John E.
Byom
|
| |
☐
Celeste A.
Clark
|
| |
☐
James C. D’Arecca
|
| | | | | | | | | |
| | | |
☐
Sheila A.
Hopkins
|
| |
☐
John F.
Kelly
|
| |
☐
Dawn M.
Zier
|
| | | | | | | | | | | | |
|
2
|
| |
To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Prestige Consumer Healthcare Inc. for the fiscal year ending March 31, 2025
|
| |
|
| |
FOR
|
| |
29
|
| |||||||||
|
3
|
| |
To vote on a non-binding resolution to approve the compensation of our named executive officers as disclosed in our Proxy Statement
|
| |
|
| |
FOR
|
| |
31
|
| |||||||||
|
4
|
| |
To vote for the approval of the Amendments to our Amended and Restated Certificate of Incorporation
|
| |
|
| |
FOR
|
| |
32
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
75
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
76
|
|
|
In order to support your Board, please sign, date and mail the enclosed proxy card to vote FOR the election of the seven director nominees nominated by your Board, FOR the ratification of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm, FOR the approval of the compensation of our named executive officers and FOR approval of the Amendments to our Amended and Restated Certificate of Incorporation. You may also vote over the internet using the internet address on the proxy card. If your shares are held in “street name”, you should follow the instructions on your voting instruction card to provide specific instructions to your bank or broker to vote as described above.
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
77
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
78
|
|
| | | |
YEAR ENDED MARCH 31,
|
| |||||||||
|
(DOLLAR VALUES IN THOUSANDS)
|
| |
2024
|
| |
2023
|
| ||||||
| GAAP Net Income (Loss) | | | | $ | 209,339 | | | | | $ | (82,306) | | |
| Interest Expense, net | | | | | 67,160 | | | | | | 69,164 | | |
| Provision (benefit) for income taxes | | | | | 66,686 | | | | | | (11,609) | | |
| Depreciation and amortization | | | | | 30,675 | | | | | | 32,625 | | |
| Non-GAAP EBITDA | | | | | 373,860 | | | | | | 7,874 | | |
| Goodwill and Tradename impairment | | | | | — | | | | | | 370,217 | | |
| Non-GAAP Adjusted AIP EBITDA | | | | $ | 373,860 | | | | | $ | 378,091 | | |
| | | |
YEAR ENDED MARCH 31,
|
| |||||||||||||||||||||
|
(DOLLAR VALUES IN THOUSANDS, EXCEPT PER SHARE DATA)
|
| |
2024
|
| |
2023
|
| ||||||||||||||||||
|
NET INCOME
|
| |
EPS
|
| |
NET INCOME
|
| |
EPS
|
| |||||||||||||||
| GAAP Net Income (Loss) | | | | $ | 209,339 | | | | | $ | 4.17 | | | | | ($ | 82,306) | | | | | ($ | 1.63) | | |
| Adjustments | | | | | | | | | | | | | | | | | | | | | | | | | |
| Goodwill and Tradename Impairment | | | | | — | | | | | | — | | | | | | 370,217 | | | | | | 7.35 | | |
| Tax impact of adjustments | | | | | — | | | | | | — | | | | | | (88,852) | | | | | | (1.76) | | |
| Normalized tax rate adjustment | | | | | 1,983 | | | | | | 0.04 | | | | | | 12,915 | | | | | | 0.26 | | |
| Total adjustments | | | | | 1,983 | | | | | | 0.04 | | | | | | 294,280 | | | | | | 5.85 | | |
|
Non-GAAP Adjusted Net Income and Non-GAAP Adjusted EPS
|
| | | $ | 211,322 | | | | | $ | 4.21 | | | | | $ | 211,974 | | | | | $ | 4.21 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
A-1
|
|
| | | |
YEAR ENDED MARCH 31,
|
| |||||||||
|
(IN THOUSANDS)
|
| |
2024
|
| |
2023
|
| ||||||
| GAAP Net Income (Loss) | | | | $ | 209,339 | | | | | $ | (82,306) | | |
| Adjustments: | | | | | | | | | | | | | |
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities as shown in the Statement of Cash Flows
|
| | | | 79,418 | | | | | | 365,877 | | |
| Changes in operating assets and liabilities as shown in the Statement of Cash Flows | | | | | (39,831) | | | | | | (53,855) | | |
| Total adjustments | | | | | 39,587 | | | | | | 312,022 | | |
| GAAP Net cash provided by operating activities | | | | | 248,926 | | | | | | 229,716 | | |
| Purchase of property and equipment | | | | | (9,550) | | | | | | (7,784) | | |
| Non-GAAP Adjusted Free Cash Flow | | | | $ | 239,376 | | | | | $ | 221,932 | | |
|
(DOLLAR VALUES IN MILLIONS)
|
| |
FY 2022 TO 2024
TOTAL |
| |||
| GAAP Total Revenues | | | | $ | 3,339.9 | | |
| GAAP Net Income | | | | $ | 332.4 | | |
| Interest expense, net | | | | | 200.6 | | |
| Provision for income taxes | | | | | 112.2 | | |
| Depreciation & amortization | | | | | 95.4 | | |
| Non-GAAP EBITDA | | | | $ | 740.6 | | |
| Inventory step-up charges associated with acquisition in Cost of Sales | | | | | 1.6 | | |
| Costs associated with acquisition in General and Administrative Expense | | | | | 5.1 | | |
| Goodwill and tradename impairment | | | | | 370.2 | | |
| Loss on extinguishment of debt and disposal of assets | | | | | 2.1 | | |
| Adjustments to EBITDA | | | | | 379.0 | | |
| Non-GAAP Adjusted EBITDA used for May 2021 Performance Share Grant Payout | | | | $ | 1,119.6 | | |
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
A-2
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
B-1
|
|
| Prestige Consumer Healthcare Inc. 2024 Proxy Statement | | |
B-2
|
|